期刊文献+

多发性硬化病人体内高水平cICAM-1和TNF-α的研究(英文) 被引量:1

The high levels of cICAM-1 and TNF-α in patients with multiple sclerosis
下载PDF
导出
摘要 目的研究多发性硬化(MS)免疫异常过程中肿瘤坏死因子(TNF-α)和循环细胞间粘附分子-1(cICAM-1)的变化及与血脑屏障(BBB)的相关性。方法用酶联免疫吸附试验(ELISA)及单项琼脂扩散(SIRD)检测临床确诊为MS的31例病人血清及脑脊液(CSF)中TNF-α、cICAM-1及白蛋白(Alb)比值。结果①31例MS患者中Alb比值轻度异常8例(25%),正常者23例;IgG指数增高(>0.7)者21例(68%)。②MS组CSF及血清中可检出高水平TNF-α,较对照组显著增高(P<0.01,P<0.05);CSF中cICAM-1水平较对照组增高明显,差异有显著性(P<0.01)。③活动性MS患者CSF中TNF-α水平较静止期增高,差异有显著性(P<0.01)。两组cICAM-1水平也有显著差异(P<0.05)。④BBB轻微损害 MS的 CSF中 cICAM-1水平较 BBB正常组增高,且与 CSF中 TNF-α水平呈正相关(r=0.478)。结论CSF及血清中高水平TNF-α与cICAM-1可能在MS病人鞘内炎症病理机制中起重要作用,cICAM-1可能成为MS活动的标志。一部分MS有一定程度BBB损害且? Objective To examine the changes of tumor necrosis factor-α(TNF-α) and circulating intercellular adhesion molecule-1 (cICAM-1 ) in patients with multiple sclerosis(MS) and the correlation with blood-brain barrier(BBB) .Methods Levels of cICAM-1 and TNF-α from 31 patients with clinically definite MS were detected by ELISA, and BBB function was evaluated by CSF/serum ratio and the paired CSF and serum samples. Results ①There were 8 mild abnormal(25. 8%) and 23 normal of Alb ratio in 31 MS patients. Twenty one patients (68% ) out of 31 were abnormal of IgG-Index(> 0. 7). ②In 31 MS patients, higher TNF-αlevels were determinated in serum and CSF, compared to control group(P < 0.05 and P < 0.01 respectively) .The level of cICAM-1 in CSF of MS patients was also elevated(P < 0.01). ③TNF-α level of CSF in active MS patients was higher than that in patients with stable MS.④The level of cICAM-1 in CSF of MS patients with mildly damaged BBB was higher than that in patients with normal BBB and associated with the level of TNF-α in CSF which showed a moderate correlation(r = 0.478). Conclusion The high levels of cICAM-1 and TNF-α may play an important role in intrathecal inflammatory pathogenesis in MS and cICAM-1 might be marker of activity in MS.
出处 《哈尔滨医科大学学报》 CAS 2000年第4期255-257,共3页 Journal of Harbin Medical University
关键词 多发性硬化症 肿瘤坏死因子 multiple sclerosis(MS) blood-brain barrier(BBB) tumor necrosis factor-α(TNF-a) circulating intercellular adhesion molecule-1 (cICAM-1)
  • 相关文献

参考文献1

  • 1Wang W Z,J Neurol Psychiatry China,1986年,12卷,1期,18页 被引量:1

同被引文献26

  • 1Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders [J]. Eur J Neurol, 2010, 17 (7): 893-902. 被引量:1
  • 2Drachman DB, Adams RN, Hong R, et al. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis[J]. Ann N Y Acad Sci, 2008, 1132: 305-314. 被引量:1
  • 3Morrison SL, Johnson MJ, Herzenberg LA, et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains[J]. Proc Natl Acad Sci USA, 1984, 81 (21): 6851-6855. 被引量:1
  • 4Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab [J]. Ann Oncol, 2003, 14(4): 520-535. 被引量:1
  • 5Zaja F, Russo D, Fuga G, et al. Rituximab for myasthenia gravis developing after bone marrow transplant[J]. Neurology, 2000, 55 (7): 1062-1063. 被引量:1
  • 6Collongues N, Casez O, Lacour A, et al. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter trial[J]. Muscle Nerve, 2012, 46(5): 687-691. 被引量:1
  • 7Lebrun C, Bourg V, Tieulie N, et al. Successful treatment of refractory myasthenia gravis with rituximab[J]. Eur J Neurol, 2009, 16(2): 246-250. 被引量:1
  • 8Diaz-Manera J, Martinez-Hernandez E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia[J]. Neurology, 2012, 78(3): 189-193. 被引量:1
  • 9Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project[J]. Blood, 2009, 113 (20):4834-4840. 被引量:1
  • 10Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizurnab for the treatment of paroxysmal nocturnal hemoglobinuria [J]. Nat Biotechnol, 2007, 25(11): 1256-1264. 被引量:1

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部